IOL Chemicals and Pharmaceuticals Limited
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
Key metrics
Price as of 2026-07-17
Stock price
₹148.33
Market cap
4,354 Cr
Stock P/E
35.0
P/B
2.42
Dividend yield
0.7%
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Jun 2023Standalone only | Sept 2023 | Dec 2023Standalone only | Mar 2024 | Jun 2024Standalone only | Sept 2024 | Dec 2024Standalone only | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 563 Cr | 1,108 Cr | 1,629 Cr | 2,133 Cr | 502 Cr | 1,028 Cr | 523 Cr | 528 Cr | 552 Cr | 568 Cr | 580 Cr | 619 Cr |
| Operating expenses (approx.) | 484 Cr | 958 Cr | 1,425 Cr | 1,872 Cr | 444 Cr | 922 Cr | 472 Cr | 461 Cr | 482 Cr | 504 Cr | 529 Cr | 525 Cr |
| EBITDA | 80 Cr | 151 Cr | 204 Cr | 261 Cr | 58 Cr | 106 Cr | 51 Cr | 67 Cr | 70 Cr | 64 Cr | 51 Cr | 94 Cr |
| OPM % | 14.1% | 13.6% | 12.5% | 12.2% | 11.6% | 10.4% | 9.7% | 12.7% | 12.6% | 11.3% | 8.8% | 15.2% |
| Other income | 7 Cr | 14 Cr | 23 Cr | 30 Cr | 7 Cr | 14 Cr | 4 Cr | 5 Cr | 7 Cr | 7 Cr | 5 Cr | 2 Cr |
| Interest | 4 Cr | 8 Cr | 13 Cr | 16 Cr | 2 Cr | 6 Cr | 4 Cr | 4 Cr | 4 Cr | 3 Cr | 4 Cr | 3 Cr |
| Depreciation | 14 Cr | 30 Cr | 46 Cr | 63 Cr | 17 Cr | 35 Cr | 19 Cr | 19 Cr | 20 Cr | 20 Cr | 20 Cr | 20 Cr |
| Profit before tax | 61 Cr | 112 Cr | 144 Cr | 182 Cr | 40 Cr | 65 Cr | 28 Cr | 45 Cr | 46 Cr | 40 Cr | 28 Cr | 71 Cr |
| Tax % | 25.0% | 25.5% | 26.1% | 26.0% | 24.2% | 25.0% | 26.2% | 29.7% | 25.4% | 26.0% | 25.3% | 24.9% |
| Net profit | 46 Cr | 84 Cr | 107 Cr | 134 Cr | 30 Cr | 49 Cr | 21 Cr | 31 Cr | 34 Cr | 30 Cr | 21 Cr | 53 Cr |
| EPS (₹) | ₹7.81 | ₹14.26 | ₹18.19 | ₹22.90 | ₹5.11 | ₹8.37 | ₹3.50 | ₹1.07 | ₹1.16 | ₹1.02 | ₹0.70 | ₹1.81 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2022Standalone only | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|
| Sales | 2,184 Cr | 2,217 Cr | 2,133 Cr | 2,079 Cr | 2,319 Cr | Sign in for TTM |
| Operating expenses (approx.) | 1,908 Cr | 1,991 Cr | 1,902 Cr | 1,855 Cr | 2,040 Cr | Sign in for TTM |
| EBITDA | 276 Cr | 226 Cr | 231 Cr | 225 Cr | 279 Cr | Sign in for TTM |
| OPM % | 12.7% | 10.2% | 10.8% | 10.8% | 12.0% | Sign in for TTM |
| Other income | 32 Cr | 26 Cr | 30 Cr | 22 Cr | 21 Cr | Sign in for TTM |
| Interest | 8 Cr | 16 Cr | 16 Cr | 15 Cr | 15 Cr | Sign in for TTM |
| Depreciation | 43 Cr | 46 Cr | 63 Cr | 72 Cr | 80 Cr | Sign in for TTM |
| Profit before tax | 225 Cr | 189 Cr | 182 Cr | 138 Cr | 184 Cr | Sign in for TTM |
| Tax % | 25.4% | 26.2% | 26.0% | 26.7% | 25.3% | Sign in for TTM |
| Net profit | 168 Cr | 139 Cr | 134 Cr | 101 Cr | 138 Cr | Sign in for TTM |
| EPS (₹) | ₹28.56 | ₹23.70 | ₹22.90 | ₹3.44 | ₹4.69 | Sign in for TTM |
| Dividend payout % | 21.0% | 16.9% | 21.8% | 23.2% | 21.3% | Sign in for TTM |
Sign in for TTM
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2022Standalone only | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Equity capital | 59 Cr | 59 Cr | 59 Cr | 59 Cr | 59 Cr |
| Reserves | 1,33,357 Cr | 1,449 Cr | 1,553 Cr | 1,629 Cr | 1,740 Cr |
| Borrowings | 44 Cr | 80 Cr | 33 Cr | 117 Cr | 132 Cr |
| Other liabilities | 526 Cr | 435 Cr | 600 Cr | 577 Cr | 656 Cr |
| Total liabilities | 1,960 Cr | 2,022 Cr | 2,244 Cr | 2,382 Cr | 2,587 Cr |
| Fixed assets (net) | 559 Cr | 751 Cr | 922 Cr | 1,158 Cr | 1,165 Cr |
| CWIP | 102 Cr | 81 Cr | 100 Cr | 21 Cr | 94 Cr |
| Investments | 2 Cr | 20 Cr | 3 Cr | 21 Cr | 21 Cr |
| Other assets | 1,079 Cr | 920 Cr | 1,120 Cr | 1,151 Cr | 1,228 Cr |
| Total assets | 1,960 Cr | 2,022 Cr | 2,244 Cr | 2,382 Cr | 2,587 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2022Standalone only | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Cash from operating activity | 93 Cr | 122 Cr | 290 Cr | 179 Cr | 214 Cr |
| Cash from investing | -120 Cr | -120 Cr | -191 Cr | -154 Cr | -198 Cr |
| Cash from financing | -2 Cr | -4 Cr | -92 Cr | 46 Cr | -29 Cr |
| Net cash flow | -29 Cr | -2 Cr | 6 Cr | 70 Cr | -13 Cr |
| Free cash flow (OCF − Capex) | -60 Cr | -90 Cr | 16 Cr | -35 Cr | 41 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2022Standalone only | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| ROCE % | 0.2% | 11.3% | 10.2% | 8.5% | 10.3% |
| ROE % | 0.1% | 9.2% | 8.3% | 6.0% | 7.7% |
| Debtor days | 78 | 83 | 81 | — | — |
| Inventory days | 94 | 77 | 108 | 97 | 90 |
| Days payable | 94 | 74 | 119 | — | — |
| Cash conversion cycle | 78 | 86 | 69 | 97 | 90 |
| Debt / equity | 0.03 | 0.05 | 0.02 | 0.07 | 0.07 |
| Current ratio | 2.10 | 2.02 | 2.00 | 1.89 | 1.78 |
| Net debt / EBITDA | 0.00 | 0.35 | 0.11 | 0.17 | 0.24 |
Compare with peers
Loading peers…